Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients
Status:
Recruiting
Trial end date:
2021-03-05
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the efficacy of Remdesivir and Baricitinib combination
therapy for the treatment of severe Acute Respiratory Distress Syndrome (ARDS) caused by
Coronavirus disease 2019 (COVID-19). Our aim is to compare the outcome of the "Remdesivir +
Baricitinib" combination against "Remdesivir + Tocilizumab" therapy and find the best option
for the management of ARDS in COVID-19 patients.
Phase:
Phase 3
Details
Lead Sponsor:
M Abdur Rahim Medical College and Hospital
Collaborator:
First affiliated Hospital Xi'an Jiaoting University